Robert Finizio was appointed as Director at ZyVersa Therapeutics, Inc..
“Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company”
ZyVersa Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from ZyVersa Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stephen C. Glover was appointed as Director at ZyVersa Therapeutics, Inc..
“Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company”
Christopher Twitty departed as Director at ZyVersa Therapeutics, Inc..
“David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board”
Gregory Skalicky departed as Director at ZyVersa Therapeutics, Inc..
“David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board”
Raj Mehra departed as Director at ZyVersa Therapeutics, Inc..
“David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board”
David S. Briones departed as Director at ZyVersa Therapeutics, Inc..
“David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board”
ZyVersa Therapeutics, Inc. shareholders approved Approve exclusive forum provision for certain actions in Delaware courts. at the 2022-12-08 meeting.
“Vote to approve the Forum Selection Proposal: Total Votes For Total Votes Against Abstentions 6,011,855 1,317,461 0”
ZyVersa Therapeutics, Inc. shareholders approved Approve increase in authorized capital stock to 111,000,000 shares. at the 2022-12-08 meeting.
“Vote to approve the Authorized Shares Proposal: Total Votes For Total Votes Against Abstentions 6,526,282 803,034 0”
ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to set quorum at 33 1/3% of voting power. at the 2022-12-08 meeting.
“Vote to approve the Quorum Standard Proposal: Total Votes For Total Votes Against Abstentions 6,526,283 803,033 0”
ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to require 66 2/3% vote to amend certain charter provisions. at the 2022-12-08 meeting.
“Vote to approve the Supermajority Voting Standard Proposal: Total Votes For Total Votes Against Abstentions 6,480,157 849,159 0”
ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to require 66 2/3% vote to amend bylaws. at the 2022-12-08 meeting.
“Vote to approve the Bylaws Amendment Proposal: Total Votes For Total Votes Against Abstentions 6,480,158 849,158 0”
ZyVersa Therapeutics, Inc. shareholders approved Approve general amendments to charter including name change, purpose, removal of blank check provisions, and removal of stockholder action by written consent. at the 2022-12-08 meeting.
“Vote to approve the General Amendments Proposal: Total Votes For Total Votes Against Abstentions 6,526,282 803,034 0 1”
ZyVersa Therapeutics, Inc. shareholders approved Approve adoption of Business Combination Agreement with ZyVersa Therapeutics, Inc. at the 2022-12-08 meeting.
“Vote to approve the Business Combination Proposal: Total Votes For Total Votes Against Abstentions 6,543,525 785,791 0”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.